New injection aims to melt belly fat without surgery
NCT ID NCT07608770
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2b trial tests an injection called CBL-514 to see if it can safely reduce abdominal fat. About 250 adults with moderate to high belly fat will receive either the drug or a placebo. The main goal is to measure fat reduction using MRI scans over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CBL-514 injection
- What this could lead to
- If successful, this could offer a non-surgical option to reduce belly fat in people with moderate to high abdominal fat.
- What could go wrong
- This is an early phase 2b trial, so results are not yet proven. The treatment may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBCUTANEOUS FAT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational Site 1
RECRUITINGSouth Yarra, Victoria, 3141, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.